What is the current market valuation of the US duloxetine API market?

The US duloxetine API market was valued at approximately 834.83 USD Million in 2024. Read More

What is the projected market valuation for the US duloxetine API market by 2035?

The market is projected to reach approximately 1739.54 USD Million by 2035. Read More

What is the expected CAGR for the US duloxetine API market during the forecast period?

The expected CAGR for the US duloxetine API market from 2025 to 2035 is 6.9%. Read More

Which companies are the key players in the US duloxetine API market?

Key players include Eli Lilly and Company, Teva Pharmaceuticals USA, Aurobindo Pharma USA, Hikma Pharmaceuticals USA, Mylan Pharmaceuticals, Amgen, Sandoz, and Sun Pharmaceutical Industries. Read More

What are the primary applications of duloxetine in the US market?

Duloxetine is primarily used for depression, anxiety disorders, chronic pain, and fibromyalgia. Read More

How does the market for duloxetine API segment by application perform?

The market segments by application include approximately 250.0 to 500.0 USD Million for depression and 200.0 to 400.0 USD Million for anxiety disorders. Read More

What formulation types are available in the US duloxetine API market?

Formulation types include tablets, capsules, and oral solutions, with capsules valued between 300.0 and 600.0 USD Million. Read More

What distribution channels are utilized for duloxetine API in the US?

Distribution channels include pharmacies, online retailers, and hospitals, with pharmacies generating approximately 400.0 to 850.0 USD Million. Read More

What are the end-use segments for duloxetine API in the US market?

End-use segments include hospitals, clinics, and homecare, with homecare valued between 384.83 and 789.54 USD Million. Read More

How does the US duloxetine API market's growth compare to other segments?

The US duloxetine API market appears to be growing steadily, with chronic pain applications projected to reach between 250.0 and 600.0 USD Million. Read More

US duloxetine api market

ID: MRFR/HC/11368-HCR 100 Pages Rahul Gotadki Last Updated: September 15, 2026

US Duloxetine API Market Research Report: By Application (Major Depressive Disorder, Generalized Anxiety Disorder, Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain) - Growth & Industry Forecast 2025 To 2035

US duloxetine api market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.22%

2024 Market Size$ 0.84 Million

2025 Market Size$ 0.9 Million

2035 Market Size$ 1.62 Million

Key Players

Eli Lilly and Company

Teva Pharmaceuticals USA

Inc.

Aurobindo Pharma USA

Inc.

Hikma Pharmaceuticals USA Inc.

Trends

Rising Demand for Mental Health Treatments
Technological Advancements in Manufacturing
Focus on Sustainable Practices

Opportunities

Rising Generic Drug Market
Expansion of Telehealth Services
Growing Focus on Personalized Medicine

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Depression
  2. 4.1.2 Anxiety Disorders
  3. 4.1.3 Chronic Pain
  4. 4.1.4 Fibromyalgia
2. 4.2 Healthcare, BY Formulation Type (USD Million)
  1. 4.2.1 Tablets
  2. 4.2.2 Capsules
  3. 4.2.3 Oral Solutions
3. 4.3 Healthcare, BY Distribution Channel (USD Million)
  1. 4.3.1 Pharmacies
  2. 4.3.2 Online Retailers
  3. 4.3.3 Hospitals
4. 4.4 Healthcare, BY End Use (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Homecare
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Eli Lilly and Company (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Teva Pharmaceuticals USA, Inc. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Aurobindo Pharma USA, Inc. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Hikma Pharmaceuticals USA Inc. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Mylan Pharmaceuticals Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sandoz Inc. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sun Pharmaceutical Industries Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY FORMULATION TYPE
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 US MARKET ANALYSIS BY END USE
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
16. 6.16 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 HEALTHCARE, BY END USE, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY END USE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US US duloxetine api market Market Segmentation

US duloxetine api market By Application (USD Million, 2025-2035)

Depression
Anxiety Disorders
Chronic Pain
Fibromyalgia

US duloxetine api market By Formulation Type (USD Million, 2025-2035)

Tablets
Capsules
Oral Solutions

US duloxetine api market By Distribution Channel (USD Million, 2025-2035)

Pharmacies
Online Retailers
Hospitals

US duloxetine api market By End Use (USD Million, 2025-2035)

Hospitals
Clinics
Homecare

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”